This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Alfred M. Cohen, MD; Edward W. Martin, Jr, MD; Ian Lavery, MD; John Daly, MD; Armando Sardi, MD; Delmar Aitken, MD; Kirby Bland, MD; Cathy Mojzisik, RN, MS; George Hinkle, RPh, MS

Arch Surg. 1991;126(3):349-352.

Abstract
• Preliminary data using B72.3 murine monoclonal antibody labeled with iodine 125 suggested that both clinically apparent as well as occult sites of colorectal cancer could be identified intraoperatively using a hand-held gamma detecting probe. We report the preliminary data of a multicenter trial of this approach in patients with primary or recurrent colorectal cancer. One hundred four patients with primary, suspected, or known recurrent colorectal cancer received an intravenous infusion of 1 mg of B72.3 monoclonal antibody radiolabeled with 7.4x10 Bq of iodine 125. Twenty-six patients with primary colorectal cancer and 72 patients with recurrent colorectal cancer were examined. Using the gamma detecting probe, 78% of the patients had localization of the antibody in their tumor; this included 75% of primary tumor sites and 63% of all recurrent tumor sites; 9.2% of all tumor sites identified represented occult sites detected only with the gamma detecting probe. The overall sensitivity was 77% and a predictive value of a positive detection was 78%. A total of 30 occult sites in 26 patients were identified. In patients with recurrent cancer, the antibody study provided unique data that precluded resection in 10 patients, and in another eight patients it extended the potentially curative procedure.

(Arch Surg. 1991;126:349-352)

Author Affiliations
From the Memorial Sloan-Kettering Cancer Center, New York, NY (Dr Cohen); the Ohio State University College of Medicine, Columbus (Dr Martin, Ms Mojzisik, and Mr Hinkle); the Cleveland (Ohio) Clinic Foundation (Dr Lavery); the University of Pennsylvania School of Medicine, Philadelphia (Dr Daly); the Ochsner Clinic, New Orleans, La (Dr Sardi); Loma Linda (Calif) University Medical Center (Dr Aitken); and the University of Florida Medical Center, Gainesville (Dr Bland).

Footnotes
Accepted for publication November 18, 1990.

Read before the 43rd Annual Cancer Symposium of the Society of Surgical Oncology, Washington, DC, May 21, 1990.

Reprint requests to Colorectal Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 (Dr Cohen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49{triangleup}CH2 and Murine Antibody CC49 in Colorectal Cancer Patients
Fang et al.
J Clin Pharmacol 2007;47:227-237.
ABSTRACT | FULL TEXT  

Pilot Study Using a Humanized CC49 Monoclonal Antibody (HuCC49{Delta}CH2) to Localize Recurrent Colorectal Carcinoma
Agnese et al.
Ann. Surg. Oncol. 2004;11:197-202.
ABSTRACT | FULL TEXT  

Radioimmunoguided Surgery in Colorectal Cancer Using a Genetically Engineered Anti-CEA Single-Chain Fv Antibody
Mayer et al.
Clin. Cancer Res. 2000;6:1711-1719.
ABSTRACT | FULL TEXT  

Monoclonal Antibodies for Diagnosis and Treatment
Dunn
Arch Surg 1993;128:1274-1280.
ABSTRACT  

Intraoperative Gamma Detection Probe With Presurgical Antibody Imaging in Colon Cancer
Kuhn et al.
Arch Surg 1991;126:1398-1403.
ABSTRACT